Communiqués Biogen Inc.

Actions

BIIB

US09062X1037

Produits pharmaceutiques

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 28/07/2026			Varia. 5j.	Varia. 1 janv.
205,61 ^USD	+2,73%		+2,83%	+16,83%

28/07	BIOGEN INC. : Barclays maintient son opinion neutre	ZM
24/07	BIOGEN INC. : Rothschild & Co Redburn toujours neutre sur le dossier	ZM

Communiqués

15/07	Biogen Appoints Michael J. Parini as Chief Legal Officer	GL
14/07	Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease	GL
29/06	Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen	GL
18/06	Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.	GL
05/06	Biogen's Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy	AQ
04/06	Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy	GL
04/06	EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus	GL
28/05	Biogen : Announces Webcast of Annual Meeting of Stockholders	PU
19/05	BIIB Investor Alert: Levi & Korsinsky Investigates Biogen Inc. (BIIB) for Potential Securities Fraud	BU
18/05	BIIB SHAREHOLDER INVESTIGATION: SueWallSt Investigates Biogen Inc. for Possible Securities Law Violations	PR
14/05	Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease	GL
06/05	Biogen : to Participate in the Bank of America Securities 2026 Health Care Conference	PU
29/04	Biogen : BIIB Q1 26 Earnings Presentation Final	PU
29/04	Biogen : Reports Q1 2026 Earnings	PU
29/04	Biogen : Q1 2026 Earnings Press Release Final	PU
29/04	Biogen : Q1 2026 Biogen Earnings Presentation	PU
29/04	Biogen : Reports First Quarter 2026 Results	PU
20/04	Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region	GL
06/04	Biogen : to Report First Quarter 2026 Financial Results April 29, 2026	PU
31/03	Biogen Inc. - FDA Approves New High Dose Regimen of SPINRAZA for Spinal Muscular Atrophy	AQ
31/03	Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology	GL
30/03	Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity	AQ
30/03	FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy	GL
28/03	Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity	GL
20/03	Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026	PR